Anticancer bioactive peptide combined with docetaxel and its mechanism in the treatment of breast cancer

Li,Xian; Gao,Beibei; Su,Xiulan

doi:10.3892/etm.2020.8902

Anticancer bioactive peptide combined with docetaxel and its mechanism in the treatment of breast cancer

Authors:
- Xian Li
- Beibei Gao
- Xiulan Su
View Affiliations

Affiliations: Clinical Medicine Research Center, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010050, P.R. China
Published online on: June 18, 2020 https://doi.org/10.3892/etm.2020.8902
Pages: 1917-1924
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer remains a worldwide public‑health issue. Novel drugs that increase the sensitivity and reduce the toxic side effects of chemotherapeutic agents are urgently required. The present study investigated the effect and mechanism of the short‑term intermittent administration of an anticancer bioactive peptide (ACBP), docetaxel (DTX), ACBP combined with DTX (MIX) and ACBP combined with low dose DTX (L‑MIX) to nude mice bearing human breast cancer tumors. The body weight, tumor length, tumor diameter, diet and water consumption of the tumor‑bearing nude mice were calculated. The protein and mRNA expression levels of p53, p21 and Ki67 were detected via immunohistochemistry and reverse transcription‑quantitative PCR, respectively. The results revealed that the activity level of each group of mice was consistent. However, the food and water consumption of the ACBP group was significantly increased compared with the NS group. Compared with the normal saline group, the tumor weights and volumes of the treatment groups were significantly decreased, indicating an inhibitory effect of the treatment. However, the MIX group exhibited lower tumor weights and volumes compared with the ACBP and DTX groups. Furthermore, no significant cell necrosis, edema or inflammatory cell infiltration was observed upon hematoxylin & eosin staining of the liver and spleen in all groups. The results also revealed that the p21, p53 and Ki67 protein and mRNA levels were decreased in the ACBP, DTX and MIX groups compared with the control group. Additionally, when compared with those in the MIX and L‑MIX groups, the p21 and Ki67 protein, and p53 and Ki67 mRNA levels in the ACBP and DTX groups were significantly increased. The results suggested that the short‑term intermittent use of ACBP alone had an inhibitory effect on tumor growth and improved the food and water consumption of tumor‑bearing nude mice. Furthermore, the combination of ACBP and DTX reduced toxic side effects and the dosage requirement of drugs to achieve therapeutic effects on the tumor‑bearing nude mice. Therefore, the antitumor effect of ACBP may be associated with the improvement of immune function in tumor‑bearing nude mice and ACBP may serve an antitumor role via the p53‑p21 signaling pathway in breast cancer.

View Figures

View References

1	Song CG, Hu Z, Wu J, Luo JM, Shen ZZ, Huang W and Shao ZM: The prevalence of BRCA1 and BRCA2 mutations in eastern Chinese women with breast cancer. J Cancer Res Clin Oncol. 132:617–626. 2006.PubMed/NCBI View Article : Google Scholar
2	Schild SE and Vokes EE: Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer. Ann Oncol. 27:590–599. 2016.PubMed/NCBI View Article : Google Scholar
3	Ye H, Xu HL, Shen Q, Zheng Q and Chen P: Palliative resection of primary tumor in metastatic nonfunctioning pancreatic neuroendocrine tumors. J Surg Res. 243:578–587. 2019.PubMed/NCBI View Article : Google Scholar
4	Ghafoor A, Jemal A, Ward E, Cokkinides V, Smith R and Thun M: Trends in breast cancer by race and ethnicity. Ca Cancer J Clin. 53:342–355. 2003.PubMed/NCBI View Article : Google Scholar
5	Feng RM, Zong YN, Cao SM and Xu RH: Current cancer situation in China: Good or bad news from the 2018 global cancer statistics? Cancer Commun (Lond). 39(22)2019.PubMed/NCBI View Article : Google Scholar
6	Culakova E, Thota R, Poniewierski MS, Kuderer NM, Wogu AF, Dale DC, Crawford J and Lyman GH: Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: A nationwide prospective cohort study. Cancer Med. 3:434–444. 2014.PubMed/NCBI View Article : Google Scholar
7	Verbelen H, Tjalma W, Meirte J and Gebruers N: Long-term morbidity after a negative sentinel node in breast cancer patients. Eur J Cancer Care (Engl). 28(e13077)2019.PubMed/NCBI View Article : Google Scholar
8	Le DL, Cao H and Yang LX: Cardiotoxicity of molecular-targeted drug therapy. Anticancer Res. 34:3243–3249. 2014.PubMed/NCBI
9	Feng QJ, Zhang F, Huang XY and Wu ZX: Effectiveness and complications of anthracycline and taxane in the therapy of breast cancer: A meta-analysis. Pathol Oncol Res. 20:179–184. 2014.PubMed/NCBI View Article : Google Scholar
10	Rivera E and Cianfrocca M: Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 75:659–670. 2015.PubMed/NCBI View Article : Google Scholar
11	Andreopoulou E and Sparano JA: Chemotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer: An overview. Curr Breast Cancer Rep. 5:42–50. 2013.PubMed/NCBI View Article : Google Scholar
12	Kayl AE and Meyers CA: Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients. Curr Opin Obstet Gynecol. 18:24–28. 2006.PubMed/NCBI View Article : Google Scholar
13	Yavari B, Mahjub R, Saidijam M, Raigani M and Soleimani M: The potential use of peptides in cancer treatment. Curr Protein Pept Sci. 19:759–770. 2018.PubMed/NCBI View Article : Google Scholar
14	Albenzio M, Santillo A, Caroprese M, Della Malva A and Marino R: Bioactive peptides in animal food products. Foods. 6(E35)2017.PubMed/NCBI View Article : Google Scholar
15	Bhat ZF, Kumar S and Bhat HF: Antihypertensive peptides of animal origin: A review. Crit Rev Food Sci Nutr. 57:566–578. 2017.PubMed/NCBI View Article : Google Scholar
16	Cicero AFG, Fogacci F and Colletti A: Potential role of bioactive peptides in prevention and treatment of chronic diseases: A narrative review. Br J Pharmacol. 174:1378–1394. 2017.PubMed/NCBI View Article : Google Scholar
17	Hilchie AL, Hoskin DW and Power Coombs MR: Anticancer activities of natural and synthetic peptides. Adv Exp Med Biol. 1117:131–147. 2019.PubMed/NCBI View Article : Google Scholar
18	Xing Z, Yu L, Li X and Su X: Anticancer bioactive peptide-3 inhibits human gastric cancer growth by targeting miR-338-5p. Cell Biosci. 6(53)2016.PubMed/NCBI View Article : Google Scholar
19	Su X, Dong C, Zhang J, Su L, Wang X, Cui H and Chen Z: Combination therapy of anti-cancer bioactive peptide with cisplatin decreases chemotherapy dosing and toxicity to improve the quality of life in xenograft nude mice bearing human gastric cancer. Cell Biosci. 4(7)2014.PubMed/NCBI View Article : Google Scholar
20	Li X, Xia L, Ouyang X, Suyila Q, Su L and Su X: Bioactive peptides sensitize cells to anticancer effects of oxaliplatin in human colorectal cancer xenografts in nude mice. Protein Pept Lett. 26:512–522. 2019.PubMed/NCBI View Article : Google Scholar
21	Ma J, Hu X, Li J, Wu D, Lan Q, Wang Q, Tian S and Dong W: Enhancing conventional chemotherapy drug cisplatin-induced anti-tumor effects on human gastric cancer cells both in vitro and in vivo by thymoquinone targeting PTEN gene. Oncotarget. 8:85926–85939. 2017.PubMed/NCBI View Article : Google Scholar
22	Yu L, Yang L, An W and Su X: Anticancer bioactive peptide-3 inhibits human gastric cancer growth by suppressing gastric cancer stem cells. J Cell Biochem. 115:697–711. 2014.PubMed/NCBI View Article : Google Scholar
23	Zhang S, Guan J, Sun M, Zhang D, Zhang H, Sun B, Guo W, Lin B, Wang Y, He Z, et al: Self-delivering prodrug-nanoassemblies fabricated by disulfide bond bridged oleate prodrug of docetaxel for breast cancer therapy. Drug Deliv. 24:1460–1469. 2017.PubMed/NCBI View Article : Google Scholar
24	Chi CL, Li FW, Liu HB, Feng SY, Zhang YJ, Zhou D and Zhang RG: Docetaxel-loaded biomimetic nanoparticles for targeted lung cancer therapy in vivo. J Nanoparticle Res. 21(144)2019.
25	Li C, Wang Z, Wang Q, Ka Yan Ho RL, Huang Y, Chow MSS, Kei Lam CW and Zuo Z: Enhanced anti-tumor efficacy and mechanisms associated with docetaxel-piperine combination- in vitro and in vivo investigation using a taxane-resistant prostate cancer model. Oncotarget. 9:3338–3352. 2017.PubMed/NCBI View Article : Google Scholar
26	Grover A, Hirani A, Pathak Y and Sutariya V: Brain-targeted delivery of docetaxel by glutathione-coated nanoparticles for brain cancer. AAPS PharmSciTech. 15:1562–1568. 2014.PubMed/NCBI View Article : Google Scholar
27	Stacul F, Bertolotto M, De Gobbis F, Calderan L, Cioffi V, Romano A, Zanconati F and Cova MA: US colour-Doppler US and fine-needle aspiration biopsy in the diagnosis of thyroid nodules. Radiol Med. 112:751–762. 2007.PubMed/NCBI View Article : Google Scholar : (In English, Italian).
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
29	Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast cancer in China. Lancet Oncol. 15:e279–e289. 2014.PubMed/NCBI View Article : Google Scholar
30	Demichele A, Yee D and Esserman L: Mechanisms of resistance to neoadjuvant chemotherapy in breast cancer. N Engl J Med. 377:2287–2289. 2017.PubMed/NCBI View Article : Google Scholar
31	Morarji K, Mcardle O, Hui K, Gingras-Hill G, Ahmed S, Greenblatt EM, Warner E, Sridhar S, Ali AMF, Azad A and Hodgson DC: Ovarian function after chemotherapy in young breast cancer survivors. Curr Oncol. 24:e494–e502. 2017.PubMed/NCBI View Article : Google Scholar
32	Witlox L, Schagen SB, de Ruiter MB, Geerlings MI, Peeters PHM, Koevoets EW, van der Wall E, Stuiver M, Sonke G, Velthuis MJ, et al: Effect of physical exercise on cognitive function and brain measures after chemotherapy in patients with breast cancer (PAM study): Protocol of a randomised controlled trial. BMJ Open. 9(e028117)2019.PubMed/NCBI View Article : Google Scholar
33	Gokal K: Effects of physical activity on cognitive and psychosocial functioning in breast cancer patients undergoing chemotherapy: A randomised controlled trial (unpublished PhD thesis). Loughborough University, 2015.
34	Gan X and Wang L: Current situation and prospect of biotherapy of metastatic renal cell carcinoma. Chin J Cancer Biother, 2018 (In Chinese).
35	Jia Q, Wang W and Su X: Inhibitory effect of anticancer bioactive peptides on proliferation of human breast cancer nm 231 cell. J 270-275, 2007.
36	Xu M, Lu JG and Ma QJ: Research on splenic nerve and spleen Immune function. Prog Mod Biomed. 10:2177–2179. 2010.
37	Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 101:736–750. 2009.PubMed/NCBI View Article : Google Scholar
38	Li Q, Zhu Y, Hou L, Wang J, Hu G, Fang X, Hu Y, Tao T, Wei X, Tang H, et al: C23 promotes tumorigenesis via suppressing p53 activity. Oncotarget. 7:58274–58285. 2014.PubMed/NCBI View Article : Google Scholar
39	Bai S, Feng Q, Pan XY, Zou H, Chen HB, Wang P, Zhou XL, Hong YL, Song SL and Yang JL: Overexpression of wild-type p21Ras plays a prominent role in colorectal cancer. Int J Mol Med. 39:861–868. 2017.PubMed/NCBI View Article : Google Scholar
40	Koopman T, Buikema HJ, Hollema H, de Bock GH and van der Vegt B: Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: Clinical validation and inter-platform agreement. Breast Cancer Res Treat. 169:33–42. 2018.PubMed/NCBI View Article : Google Scholar
41	Morrison CD, Allington TM, Thompson CL, Gilmore HL, Chang JC, Keri RA and Schiemann WP: c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression. Oncotarget. 7:72777–72794. 2016.PubMed/NCBI View Article : Google Scholar
42	Wang K, Xie SM, He JJ, Ren Y, Xia HB and Zhang XW: Establishment of a bioluminescent MDA-MB-231 cell line for in vivo imaging of human triple-negative breast cancer xenograft. Nan Fang Yi Ke Da Xue Xue Bao. 31:1812–1818. 2011.PubMed/NCBI(In Chinese).
43	Dumay A, Feugeas JP, Wittmer E, Lehmann-Che J, Bertheau P, Espié M, Plassa LF, Cottu P, Marty M, André F, et al: Distinct tumor protein p53 mutants in breast cancers subgroups. Int J Cancer. 132:1227–1231. 2013.PubMed/NCBI View Article : Google Scholar
44	Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 486:346–352. 2012.PubMed/NCBI View Article : Google Scholar